I cant help but think getting things through fda was just made significantly easier
I can accept 33% dilution in return for significant upside of potential success which has now been given every chance to occur
The backslide in sp should now be over with official backing of big pharma which prana has never had before . I'd say a revalue is the likely outcome on NASDAQ.